Compare PGEN & ASST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PGEN | ASST |
|---|---|---|
| Founded | 1998 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2013 | 2022 |
| Metric | PGEN | ASST |
|---|---|---|
| Price | $5.64 | $13.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $8.33 | ★ $23.50 |
| AVG Volume (30 Days) | ★ 5.5M | 5.1M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.56 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $230,981,000.00 | $633,489.00 |
| Revenue This Year | $1,115.92 | $294.91 |
| Revenue Next Year | $81.04 | $12.16 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 128.67 |
| 52 Week Low | $1.47 | $0.49 |
| 52 Week High | $6.04 | $19.75 |
| Indicator | PGEN | ASST |
|---|---|---|
| Relative Strength Index (RSI) | 64.35 | 45.02 |
| Support Level | $3.32 | $0.74 |
| Resistance Level | N/A | $17.73 |
| Average True Range (ATR) | 0.34 | 1.22 |
| MACD | 0.06 | -0.23 |
| Stochastic Oscillator | 75.46 | 36.65 |
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Strive Inc is a structured finance company and institutional asset manager focused on disciplined capital allocation and long term value creation. The company has adopted bitcoin as its hurdle rate for capital deployment because of its fiduciary duty to maximize long-term value for stockholders, and compounding purchasing power over time. It operates in two reportable operating segments: the Asset Management segment, which provides investment advisory services and the Corporate & Other segment, which includes the company's bitcoin treasury operations. The majority of the revenue is derived from the Asset Management segment.